← Back to headlines
Truist Analyst Reviews Exelixis (EXEL) and Cancer Drug
A new analyst from Truist has provided insights into Exelixis (EXEL) and its next-generation cancer drug, offering a fresh perspective on the company's pharmaceutical developments.
1 Jul, 21:32 — 1 Jul, 21:32
Sources
Showing 1 of 1 sources
